TY - JOUR
T1 - Comparative effects of torasemide and furosemide in rats with heart failure
AU - Veeraveedu, Punniyakoti T.
AU - Watanabe, Kenichi
AU - Ma, Meilei
AU - Thandavarayan, Rajarajan A.
AU - Palaniyandi, Suresh S.
AU - Yamaguchi, Ken'ichi
AU - Suzuki, Kenji
AU - Kodama, Makoto
AU - Aizawa, Yoshifusa
N1 - Funding Information:
This research was supported by a Yujin Memorial Grant, Ministry of Education, Science, Sports and Culture, Japan, and by a grant from the promotion and Mutual Aid Corporation for Private Schools, Japan. We thank Gurusamy Narasimman, Sayaka Mito, and Hiroko Tanaka for their assistance in this research work. We express our sincere thank to Dr. Hitoshi Hama and Mr. Mamoru Koike (Kido hospital, Niigata, Japan) for providing facility and helping in the determination of electrolytes and to Otsuka Pharmaceutical Co. (Tokushima, Japan) for measuring plasma aldosterone and ANP to this study.
PY - 2008/2/1
Y1 - 2008/2/1
N2 - It has been reported that torasemide but not furosemide, may block the renin-angiotensin-aldosterone system and therefore it might attenuate myocardial remodeling accompanied by left ventricular (LV) dysfunction. We therefore compared the therapeutic effects of torasemide, a long-acting loop diuretic, and furosemide, a short-acting one, on the progression of LV remodeling in a rat model of chronic heart failure (CHF) after experimental autoimmune myocarditis (EAM). CHF was elicited in Lewis rats by immunization with porcine cardiac myosin. Twenty-eight days after immunization, rats were treated for 28 days with torasemide, furosemide, or vehicle. We investigated the effects on metabolic and neurohumoral parameters, cardiac fibrosis and remodeling in EAM rats. Diuresis was increased dose dependently by both torasemide and furosemide, showed an equipotent natriuretic effect. The urinary potassium excretion was significantly increased with furosemide in comparison to torasemide. Myocardial functional parameters were significantly improved by torasemide. Conversely, these parameters did not change in rats receiving furosemide. Torasemide suppressed LV fibrosis, myocardial protein levels of transforming growth factor-beta1, collagen III, and aldosterone synthase and improved survival rate to the control level, but furosemide did not. Moreover, both pharmacological interventions significantly elevated plasma angiotensin II and decreased atrial natriuretic peptide in a dose-dependent manner. Our results demonstrate that compared with furosemide, torasemide treatment significantly improved survival rate, LV function and ameliorated the progression of cardiac remodeling in rats with CHF after EAM.
AB - It has been reported that torasemide but not furosemide, may block the renin-angiotensin-aldosterone system and therefore it might attenuate myocardial remodeling accompanied by left ventricular (LV) dysfunction. We therefore compared the therapeutic effects of torasemide, a long-acting loop diuretic, and furosemide, a short-acting one, on the progression of LV remodeling in a rat model of chronic heart failure (CHF) after experimental autoimmune myocarditis (EAM). CHF was elicited in Lewis rats by immunization with porcine cardiac myosin. Twenty-eight days after immunization, rats were treated for 28 days with torasemide, furosemide, or vehicle. We investigated the effects on metabolic and neurohumoral parameters, cardiac fibrosis and remodeling in EAM rats. Diuresis was increased dose dependently by both torasemide and furosemide, showed an equipotent natriuretic effect. The urinary potassium excretion was significantly increased with furosemide in comparison to torasemide. Myocardial functional parameters were significantly improved by torasemide. Conversely, these parameters did not change in rats receiving furosemide. Torasemide suppressed LV fibrosis, myocardial protein levels of transforming growth factor-beta1, collagen III, and aldosterone synthase and improved survival rate to the control level, but furosemide did not. Moreover, both pharmacological interventions significantly elevated plasma angiotensin II and decreased atrial natriuretic peptide in a dose-dependent manner. Our results demonstrate that compared with furosemide, torasemide treatment significantly improved survival rate, LV function and ameliorated the progression of cardiac remodeling in rats with CHF after EAM.
KW - Aldosterone
KW - Experimental autoimmune myocarditis
KW - Fibrosis
KW - Furosemide
KW - Remodeling
KW - Torasemide
UR - http://www.scopus.com/inward/record.url?scp=38049043455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38049043455&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2007.09.026
DO - 10.1016/j.bcp.2007.09.026
M3 - Article
C2 - 18001696
AN - SCOPUS:38049043455
SN - 0006-2952
VL - 75
SP - 649
EP - 659
JO - Biochemical pharmacology
JF - Biochemical pharmacology
IS - 3
ER -